Ardent Health NYSE: ARDT raised the lower end of its full-year adjusted EBITDA forecast after reporting $1.62 billion in third-quarter revenue and $138 million in adjusted EBITDA, as lower labor costs and improving patient volumes supported results.

Ardent Health's revenue has plateaued near $1.6B per quarter, with year-over-year growth slowing to 2.7% in 2026Q3, suggesting top-line expansion has largely stalled after the 2025 peak.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.31+33.6% vs $0.23 | $1.6B+1.3% vs $1.6B |
Q3 2026 Aug 4, 2026 | $0.12-34.0% vs $0.18 | $1.6B+2.0% vs $1.6B |
Q2 2026 May 5, 2026 | $0.28+55.6% vs $0.18 | $1.6B+1.5% vs $1.6B |
Q2 2026 Mar 4, 2026 | $0.32-8.0% vs $0.35 | $1.6B-1.6% vs $1.6B |
Ardent Health NYSE: ARDT raised the lower end of its full-year adjusted EBITDA forecast after reporting $1.62 billion in third-quarter revenue and $138 million in adjusted EBITDA, as lower labor costs and improving patient volumes supported results.

Ardent Health, Inc. ( ARDT ) Q3 2026 Earnings Call November 5, 2026 10:00 AM EST Company Participants David Styblo - Senior Vice President of Investor Relations David Caspers - President, CEO & Director Alfred Lumsdaine - Chief Financial Officer Conference Call Participants Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Albert Rice - UBS Investment Bank, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Craig Hettenbach - Morgan Stanley, Research Division Kevin Fischbeck - BofA Securities, Research Division Jason Cassorla - Guggenheim Securities, LLC, Research Division Sean Dodge - BMO Capital Markets Equity Research Sarah Conrad - Goldman Sachs Group, Inc., Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Presentation Operator Ladies and gentlemen, thank you for joining us and welcome to the Ardent Health Third Quarter 2026 Earnings Conference Call. [Operator Instructions] I'll now hand the conference over to Dave Styblo, Lead Investor Relations.
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.52 per share a year ago.
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced results for the quarter ended September 30, 2026. Third Quarter 2026 Operating and Financial Summary All comparisons are versus the same prior year period. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key.
Benchmark ARDT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ardent Health Inc. (ARDT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.75 | $2.54B | 17.20 | 6.01% | 2.27% | 8.42% | — | |
| $501.19 | $108.51B | 16.07 | 7.08% | 8.61% | — | 0.59% | |
| $282.07 | $24.3B | 7.84 | 3.12% | 12.71% | 32.11% | — | |
| $2.02 | $284.84M | -0.53 | -1.18% | -2.34% | — | — | |
| $191.98 | $11.62B | 7.77 | 9.71% | 7.96% | 19.27% | 0.41% | |
| $186.02 | $10.84B | 27.64 | 18.72% | 7.03% | 16.61% | 0.13% |
Ardent Health Inc. (ARDT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ardent Health Inc. (ARDT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Oct 23, 2026·SEC
Aug 4, 2026·SEC
Get notified when ARDT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ardent Health Inc. (ARDT) stock FAQ — growth, dividends, profitability & financials explained
Ardent Health Inc. (ARDT) reported $6.45B in revenue over the trailing twelve months. Revenue was $6.32B in fiscal year 2025. That is 200% more than the $2.11B of fiscal year 2016.
Ardent Health Inc. (ARDT) grew revenue by 2.0% over the trailing twelve months, compared with the twelve months before.
Yes. Ardent Health Inc. (ARDT) earned $146.2M in net income over the trailing twelve months (a 2.3% net margin).
Ardent Health Inc. (ARDT) had a return on equity (ROE) of 8.4% over the trailing twelve months. That is below the market's typical 10-15%.
Ardent Health Inc. (ARDT) generated $280.7M in free cash flow over the trailing twelve months.